Holen Sie sich die Stockscreener-App
2.78
7.92%
-0.25
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Canada
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - finance.yahoo.com
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - Stock Titan
Editas Medicine Files $400 Million Mixed Shelf - marketscreener.com
O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan
Editas Medicine (EDIT) officer flags 700-share stock sale - Stock Titan
Editas Medicine stock holds steady as investors weigh latest gene editing progress - AD HOC NEWS
Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT - MarketBeat
EDIT Price History for Editas Medicine Stock - Barchart.com
Editas Medicine Inc. (EDIT) Peer Comparison – Compare with Others - Value Research
ADAR1 Capital Management LLC Buys New Stake in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026. - marketscreener.com
EDIT Should I Buy - Intellectia AI
EDIT Stock Price, Quote & Chart - ChartMill
ETFs Investing in Editas Medicine, Inc. Stocks - TradingView
Editas Medicine (NASDAQ:EDIT) Trading 14.4% HigherHere's What Happened - MarketBeat
Ladenburg Thalmann Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $6 - Moomoo
EDIT Initiates Coverage On Ladenburg ThalmannRating Set to Bu - GuruFocus
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP - MarketBeat
EDIT Q2 2026 Earnings: Narrower-than-Expected Loss Underscores Cost DisciplineRevenue Growth Report - vinanet.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan
Editas Medicine (EDIT) Slides 3.7% as Gene-Editing Stock Tests Key Support at $2.70Collar Trade - vinanet.vn
Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat
Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et
Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Singapore
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Editas Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN - TradingView
HC Wainwright Boosts Earnings Estimates for Editas Medicine - MarketBeat
Editas Medicine, Inc. (0IFK.L) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold - MarketBeat
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000 - Stock Titan
Editas Medicine, Inc. (EDIT) director reports no share or option holdings - Stock Titan
Editas Medicine, Inc. expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Editas Medicine, Inc. (0IFK.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Yahoo Finance
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):